All In Biotech

Drug Trial Radar · NCT05510544

Plerixafor for Poorly Mobilized Lymphoma

Efficacy and Safety of Plerixafor in Patients With Poorly Mobilized Lymphoma

Last checked: Nov 20, 2026Latest source record: Mar 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 19, 2022

Primary completion

Dec 20, 2023

Study completion Jan 31, 2024

Sponsor

Lead sponsor
Peking UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Autologous hematopoietic stem cell transplantation is one of the effective means of lymphoma treatment, but patients who receive transplantation in the absence of sufficient stem cell numbers have a delay in stem cell engraftment and a markedly increased risk of infection and emergence. Plerixafor injection is a strong and specific antagonist of CXCR4. It can rapidly mobilize stem cells from bone marrow into peripheral blood circulation by blocking the combination of SDF1 and CXCR4. Studies have shown that the simultaneous use of plerixafor injection and G-CSF can collect more hematopoietic stem cells in a certain period of time than cancer patients who use G-CSF alone. This multicenter, open-label, single-arm study was designed to evaluate the efficacy and safety of plerixafor injection for hematopoietic stem cell mobilization in poorly mobilized lymphoma patients.

Conditions

  • Lymphoma

Interventions

  • Plerixafor,G-CSFDrug

    G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8. Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the proportion of patients achieving ≥2 × 10ˆ6/kg CD34+ HSCs within ≤4 apheresis sessions.Time frame: within 4 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.